IPG Photonics (IPGP) Targets Lumibird Medical, Is The Stock Still Undervalued?
IPG Photonics (IPGP) has drawn fresh attention after signing a binding offer to acquire Lumibird Medical, a move that would expand its medical laser business and reshape the mix of its Advanced Solutions revenue.
See our latest analysis for IPG Photonics.
IPG Photonics’ latest share price of $104.33 comes after a 1-day share price return of 0.94%. However, the 30-day and 90-day share price returns are down 8.19% and 16.55% respectively. The year-to-date share price return of 39.40% and 1-year total shareholder return of 39.80% contrast with a 5-year total shareholder return that is down 51.58%, suggesting shorter term momentum has improved compared with a weaker longer term track record.
If this medical expansion has your attention, it could be a good moment to widen your watchlist and check out 39 healthcare AI stocks
IPG Photonics is increasingly focusing on higher margin medical lasers, while the stock has already rebounded sharply this year. Does that shifting mix still leave enough upside to justify the risks at today’s price?
Most Popular Narrative: 20.1% Undervalued
On the most followed narrative, IPG Photonics is priced at $104.33 against a fair value estimate of $130.50, putting the focus squarely on what would need to go right for that gap to close.
New growth initiatives in medical (e.g., thulium lasers for urology), semiconductor, and micromachining end-markets are gaining early traction, diversifying revenue streams and supporting higher margins over time as these higher-value verticals scale.
Curious what kind of revenue trajectory and margin lift would justify that higher fair value for IPG Photonics? The narrative leans on faster earnings growth, richer profitability and a premium future earnings multiple that is well above the wider US Electronic industry. The full breakdown shows how those pieces are expected to work together.
Result: Fair Value of $130.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, IPG Photonics still faces pressure from tariff and geopolitical risks, along with softer materials processing demand, which could challenge the upbeat growth assumptions.
Find out about the key risks to this IPG Photonics narrative.
Another View on IPG Photonics’ Valuation
The analysts’ $130.50 fair value for IPG Photonics contrasts with how the stock looks on simple sales based measures. IPG Photonics trades on a P/S of 4.3x, compared with 2.8x for the wider US Electronic industry, peers at 1.6x, and a fair ratio of 2.9x. This implies investors are already paying a clear premium. Is that premium something you are comfortable with?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed sentiment around IPG Photonics and its medical push, now is a good time to review the data yourself and weigh both sides using 3 key rewards and 3 important warning signs
Looking for more ideas beyond IPG Photonics?
If IPG Photonics has sharpened your interest, do not stop there. Broader context from other stocks can really strengthen your next move.
- Spot fresh potential by scanning screener containing 20 high quality undiscovered gems that combine strong fundamentals with less market attention.
- Strengthen your core holdings by using the solid balance sheet and fundamentals stocks screener (47 results) to focus on companies with sturdier financial foundations.
- Shift your attention to stability and income by reviewing 8 dividend fortresses that could complement a growth focused position in IPG Photonics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com